Aspecte clinico-farmacologice ale heptralului în tratamentul steatohepatitei non-alcoolice
Закрыть
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
1254 7
Ultima descărcare din IBN:
2024-03-12 08:49
SM ISO690:2012
DAVID, Ludmila, GHICAVÂI, Victor, BUTOROV, Ivan, STOLEAR, Anton, BUTOROV, Valentina, NECULA, Gheorghe. Aspecte clinico-farmacologice ale heptralului în tratamentul steatohepatitei non-alcoolice. In: Curierul Medical, 2010, nr. 3(315), pp. 98-104. ISSN 1875-0666.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Curierul Medical
Numărul 3(315) / 2010 / ISSN 1875-0666

Aspecte clinico-farmacologice ale heptralului în tratamentul steatohepatitei non-alcoolice

Pag. 98-104

David Ludmila, Ghicavâi Victor, Butorov Ivan, Stolear Anton, Butorov Valentina, Necula Gheorghe
 
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“
 
Disponibil în IBN: 15 decembrie 2013


Rezumat

Clinical and Pharmacological Aspects of Heptral in the Treatment of Non-alcoholic Steatohepatitis The study included 50 patients with NASH. Among them were 15 men and 35 women. Initially all patients had abdominal type obesity. Overweight body mass was diagnosed in 5 patients, 5 – I degree obesity, 8 – II degree, 7 – degree III and IV. Heptral is a pharmaceutical preparation with positive influence on the main pathogenetic links of steatohepatitis. Including Heptral in the complex therapy of patients with non-alcoholic steatohepatitis decreased the activity of enzymes of cytolysis, significantly improved the lipid peroxidation and hormonal status indices in comparison with the basic therapy. Heptral also improved patients’ quality of life.

Cuvinte-cheie
Heptral,

non-alcoholic steatohepatitis

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-5465</cfResPublId>
<cfResPublDate>2010-06-01</cfResPublDate>
<cfVol>315</cfVol>
<cfIssue>3</cfIssue>
<cfStartPage>98</cfStartPage>
<cfISSN>1875-0666</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/5465</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Aspecte clinico-farmacologice ale heptralului în tratamentul steatohepatitei non-alcoolice</cfTitle>
<cfKeyw cfLangCode='RO' cfTrans='o'>Heptral; non-alcoholic steatohepatitis</cfKeyw>
<cfAbstr cfLangCode='EN' cfTrans='o'>Clinical and Pharmacological Aspects of Heptral in the Treatment of Non-alcoholic Steatohepatitis
The study included 50 patients with NASH. Among them were 15 men and 35 women. Initially all patients had abdominal type obesity.
Overweight body mass was diagnosed in 5 patients, 5 – I degree obesity, 8 – II degree, 7 – degree III and IV. Heptral is a pharmaceutical
preparation with positive influence on the main pathogenetic links of steatohepatitis. Including Heptral in the complex therapy of patients with
non-alcoholic steatohepatitis decreased the activity of enzymes of cytolysis, significantly improved the lipid peroxidation and hormonal status
indices in comparison with the basic therapy. Heptral also improved patients’ quality of life.</cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-25853</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11721</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11683</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-30133</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-10737</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-30122</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-25853</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-25853-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
<cfFamilyNames>David</cfFamilyNames>
<cfFirstNames>Ludmila</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11721</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11721-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Ghicavîi</cfFamilyNames>
<cfFirstNames>Victor</cfFirstNames>
<cfFamilyNames>Гикавый</cfFamilyNames>
<cfFirstNames>Виктор</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11683</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11683-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Буторов</cfFamilyNames>
<cfFirstNames>Иван</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-30133</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-30133-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Stolear</cfFamilyNames>
<cfFirstNames>Anton</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-10737</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10737-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Butorov</cfFamilyNames>
<cfFirstNames>Valentina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-30122</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-30122-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2010-06-01T24:00:00</cfStartDate>
<cfFamilyNames>Necula</cfFamilyNames>
<cfFirstNames>Gheorghe</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>